05.27.26 -- Why Clinical And Commercial Development Must Be Integrated Fully And Early

Rare disease trials demand inventive design. Uncover creative strategies that help sponsors overcome tiny populations, complex endpoints, and operational hurdles to advance meaningful breakthroughs.

Last year was by some distance the best year ever in terms of new active substances. Explore the 105 new debuts that easily outstrips that of the previous record holder, 2021’s, 97.

Phase 2 neuro endpoints can miss subtle change. Learn when composites help or hinder, how to align cognition, function, and biomarkers with real-world data for go/no-go decisions.

Stop letting rigid legacy RTSM systems stall your clinical trials. Learn why manual change requests cause months of delays and how a modern, platform-based approach restores your study’s agility.

Discover how to transform logistical challenges into strategic advantages with flexible, forward-looking solutions designed for today’s dynamic clinical development landscape.

This report examines how amendment drivers vary across therapeutic areas and how those changes impact execution, patient burden, site workload, timelines, and study costs.

By incorporating flexibility, statistical rigor, and continuous learning, adaptive designs strengthen early-phase oncology programs and support faster, more confident progression into later-stage development.

Implement an RTSM solution designed to support all study designs and empower teams to easily manage randomization and trial supply workflows with flexibility and precision.

Streamline your clinical trial operations with a fast, guided system implementation tailored to your team’s medication management needs.

From complex study designs and evolving regulations to time-sensitive treatment protocols, advancing oncology clinical trials present significant challenges for investigators, sites, and patients.